Equities

InventisBio Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

InventisBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.43
  • Today's Change0.03 / 0.13%
  • Shares traded13.58m
  • 1 Year change+86.84%
  • Beta1.5134
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

InventisBio Co Ltd is a China-based company primarily engaged in the research and development of innovative drugs. The Company’s main products are currently in clinical development. The Company's products focus on major disease areas such as oncology, metabolic diseases, and autoimmune diseases. Its products include D-0502, D-0120, D-2570, and BPI-D0316. The Company mainly conducts its businesses within domestic market.

  • Revenue in CNY (TTM)180.53m
  • Net income in CNY-116.28m
  • Incorporated2013
  • Employees185.00
  • Location
    InventisBio Co LtdNo.4 Building, Lane 67, Libing RoadSHANGHAI 201203ChinaCHN
  • Phone+86 2 150778527
  • Fax+86 2 150778527
  • Websitehttps://www.inventisbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Yahong Meditech Co Ltd279.02m-362.17m7.00bn391.00--3.95--25.10-0.642-0.6420.49333.100.12511.164.19713,603.90-16.84-14.30-19.15-15.0172.2273.78-134.65-703.804.96--0.1545--1,365.55--4.09--50.48--
GemPharmatech Co Ltd752.70m121.51m7.20bn1.58k58.373.27--9.560.30070.30071.865.370.28074.511.88476,993.404.537.695.428.9661.8468.1716.1425.583.17--0.129521.9410.3928.94-30.8925.8820.02--
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.48bn1.36k54.966.43--7.351.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Shanghai Medicilon Inc1.08bn-231.86m9.00bn2.27k--4.36--8.34-1.75-1.758.0415.360.37598.561.68459,338.00-8.083.66-9.994.6316.2731.15-21.496.672.19--0.150840.97-24.0118.22-896.21--2.54--
Bio-Thera Solutions Ltd845.32m-368.84m9.95bn1.17k--20.55--11.77-0.8908-0.89082.041.170.37020.77225.96---16.15-16.38-33.76-22.2274.9977.05-43.63-62.110.4617-34.120.573--5.44302.90-29.34--11.14--
HitGen Inc498.51m114.11m12.06bn483.00106.648.20--24.200.28240.28241.243.670.27266.374.691,032,114.006.183.066.873.3655.2353.5522.6714.485.126.590.167434.3214.9910.0826.13-15.653.16--
InventisBio Co Ltd180.53m-116.28m13.53bn185.00--8.13--74.97-0.2012-0.20120.31222.880.0988--1.03975,824.70-6.36-32.89-6.76-35.2299.41---64.41-682.73----0.0127---9.0225.0015.41---3.97--
Mabwell Shanghai Bioscience Co Ltd624.52m-947.49m14.51bn1.36k--19.06--23.23-2.37-2.371.561.900.13840.345814.57441,048.00-21.06-29.90-36.19-36.1888.7285.56-152.14-1,188.680.8093-10.820.7353--56.2846.680.9031--12.25--
Sinocelltech Group Ltd1.89bn-310.15m17.92bn2.28k------9.50-0.6964-0.69644.24-0.10830.54580.43253.04828,989.10-8.37-22.66-29.60-48.2593.5195.52-15.33-42.960.5008-0.67531.02--33.13294.24127.39--23.95--
BeBetter Med Inc-100.00bn-100.00bn19.09bn150.00--88.65----------0.4785----------------------------0.0116------67.59------
Data as of Feb 10 2026. Currency figures normalised to InventisBio Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

25.32%Per cent of shares held by top holders
HolderShares% Held
China Universal Asset Management Co., Ltd.as of 30 Jun 202525.07m6.00%
Foresight Fund Management Co., Ltd.as of 31 Mar 202513.17m3.30%
Ping An Fund Management Co., Ltd.as of 30 Jun 202510.53m2.52%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202510.09m2.42%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20259.97m2.39%
JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 20258.69m2.08%
Penghua Fund Management Co., Ltd.as of 30 Jun 20257.11m1.70%
Harvest Fund Management Co., Ltd.as of 30 Jun 20256.90m1.65%
National Council for Social Security Fundas of 31 Mar 20256.67m1.67%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 20256.63m1.59%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.